Entinostat
SNDX-275-0303
Phase 2 small_molecule completed
Quick answer
Entinostat for ER+ Breast Cancer is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- ER+ Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed